Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis in malignant lymphoma.

Ad Koster1, John M M Raemaekers

  • 1Department of Haematology, University Medical Centre Nijmegen, The Netherlands.

Current Opinion in Oncology
|October 15, 2005
PubMed
Summary

Angiogenesis, the formation of new blood vessels, is crucial in lymphoma development and progression. Targeting tumor vascularization offers a promising therapeutic strategy for lymphoma patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarkers in Relation to Patency, Popliteal Reflux, and Post-thrombotic Syndrome: A Subanalysis of the Ultrasound-accelerated Catheter-directed Thrombolysis versus Anticoagulation for the Prevention of Post-thrombotic Syndrome Trial.

Thrombosis and haemostasis·2026
Same author

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials.

Journal of cancer survivorship : research and practice·2024
Same author

Relationships, marriage, and partner abandonment among Hodgkin lymphoma survivors treated in nine EORTC-GELA Lymphoma Group trials.

Leukemia & lymphoma·2024
Same author

Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trials.

Acta oncologica (Stockholm, Sweden)·2023
Same author

Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials.

British journal of haematology·2022

Area of Science:

  • Oncology
  • Hematology
  • Vascular Biology

Background:

  • Angiogenesis is integral to the pathophysiology of both solid tumors and hematologic malignancies.
  • Tumor-associated blood vessels are increasingly recognized as a therapeutic target.
  • This review focuses on the role of angiogenesis in malignant lymphoma and its therapeutic implications.

Purpose of the Study:

  • To review the evidence supporting the role of angiogenesis in malignant lymphoma.
  • To discuss the therapeutic implications of targeting angiogenesis in lymphoma.

Main Methods:

  • Review of existing literature on angiogenesis in lymphoma.
  • Analysis of studies investigating tumor vascularization and its correlation with lymphoma subtypes and disease stage.
  • Examination of the role of vascular endothelial growth factor (VEGF) and its receptors in lymphoma.
  • Evaluation of preclinical and early clinical data on anti-angiogenic therapies in lymphoma.

Main Results:

  • Lymphoma cells exhibit angiogenic properties, and tumor vascularization is higher in lymphoma tissue compared to reactive lymph nodes.
  • Increased vascularization correlates with more aggressive lymphoma subtypes and advanced stages.
  • High vascular endothelial growth factor (VEGF) levels are linked to poor prognosis.
  • VEGF and its receptors are present in lymphoma cells, and anti-VEGF therapy shows efficacy in animal models.
  • Heterogeneity in angiogenesis and blood vessel phenotype exists among lymphoma subtypes, impacting therapeutic strategies.

Conclusions:

  • Angiogenesis clearly plays a significant role in malignant lymphoma.
  • Tumor vasculature represents an attractive target for lymphoma therapy.
  • Subtype-specific differences in angiogenesis must be considered when selecting patients for anti-angiogenic therapy trials.

Related Experiment Videos